News
IPSC
1.630
-6.32%
-0.110
Century Therapeutics Reports Third Quarter 2026 Financial Results
NASDAQ · 6h ago
Century Therapeutics reports Q3 EPS (11c), consensus (11c)
TipRanks · 20h ago
Century Therapeutics GAAP EPS of -$0.11 beats by $0.01
Seeking Alpha · 21h ago
Century Therapeutics, Inc. Q3 Loss Declines
NASDAQ · 21h ago
*Century Therapeutics 3Q Rev $0.00 >IPSC
Dow Jones · 21h ago
*Century Therapeutics 3Q Loss $23.5M >IPSC
Dow Jones · 21h ago
Press Release: Century Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
Dow Jones · 21h ago
Weekly Report: what happened at IPSC last week (1102-1106)?
Weekly Report · 4d ago
We're Keeping An Eye On Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate
Simply Wall St · 11/05 10:36
Weekly Report: what happened at IPSC last week (1026-1030)?
Weekly Report · 11/02 09:15
Weekly Report: what happened at IPSC last week (1019-1023)?
Weekly Report · 10/26 09:15
Weekly Report: what happened at IPSC last week (1012-1016)?
Weekly Report · 10/19 09:15
Weekly Report: what happened at IPSC last week (1005-1009)?
Weekly Report · 10/12 09:16
Analysts Offer Insights on Healthcare Companies: Century Therapeutics (IPSC), Glaukos (GKOS) and Praxis Precision Medicines (PRAX)
TipRanks · 10/06 10:50
Weekly Report: what happened at IPSC last week (0928-1002)?
Weekly Report · 10/05 09:16
Century Therapeutics advances CNTY-813 islet therapy program
TipRanks · 10/02 12:48
Century Therapeutics announces presentation of nonclinical data for CNTY-813
TipRanks · 10/02 12:15
Century Therapeutics Presents CNTY-813 Nonclinical Data At EASD 2026
Benzinga · 10/02 12:07
Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026
Barchart · 10/02 07:05
Century Therapeutics: Competitors May Be Quietly De-Risking Its Biggest Bet
Seeking Alpha · 09/30 08:27
More
Webull provides a variety of real-time IPSC stock news. You can receive the latest news about Century Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About IPSC
Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy.